Janux Therapeutics Inc Sustainability Reports
Janux Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing next-generation therapeutics for cancer. The company utilizes its proprietary Tumor Activated T Cell Engager (TRACTr) and tumor-activated immunomodulator (TRACIr) platform technologies to engineer precision immunotherapies designed to target tumors while minimizing systemic toxicity.
Sector: Manufacturing
Country: United States
Exchange: Nasdaq
FIGI: BBG00ZHSKH39
3 reports from 2021 to 2024
